Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599463 | 0.90 | PTGS2 (0.51) | PTGS2KMT2ACFDLMNAAKT1 | |
| SCHEMBL18020601 | 0.89 | PTGS2 (0.53) | PTGS2KMT2ACFDLMNAAKT1 | |
| SCHEMBL16599395 | 0.88 | PTGS2 (0.55) | PTGS2KMT2ACFDLMNAKDM4E | |
| SCHEMBL16610065 | 0.86 | PTGS2 (0.53) | PTGS2KMT2ACFDLMNAAKT1 | |
| SCHEMBL19040078 | 0.82 | LMNA (0.49) | PTGS2KMT2ACFDLMNAKDM4E | |
| SCHEMBL4134522 | 0.82 | PTGS2 (0.73) | PTGS2KMT2ALMNAF2KDM4E | |
| SCHEMBL17986205 | 0.81 | PTGS2 (0.46) | PTGS2KMT2ACFDLMNA | |
| SCHEMBL19054604 | 0.80 | LMNA (0.62) | PTGS2KMT2ACFDLMNAKDM4E | |
| SCHEMBL16610073 | 0.79 | PTGS2 (0.44) | PTGS2KMT2ACFDLMNAKDM4E | |
| SCHEMBL18020602 | 0.78 | PTGS2 (0.53) | PTGS2KMT2ACFDLMNAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| WO-2015044177-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | APC, BRCA1, VHL | PTGS2 514/4885KMT2A 3041/4885CFD 3054/4885 |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | APC, BRCA1, VHL | PTGS2 514/4885KMT2A 3041/4885CFD 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.